ATOX1-IN-1
ATOX1-IN-1 is an inhibitor of ATOX1 (a copper chaperone protein) with a Kd value of 12.5 μM. ATOX1-IN-1 induces intracellular copper accumulation, increases the level of DNA methylation in the NOTCH1 promoter region, and inhibits the NOTCH1/HES1 signaling pathway. ATOX1-IN-1 enhances the sensitivity of hepatocellular carcinoma cells to Cisplatin (HY-17394). ATOX1-IN-1 can be used in hepatocellular carcinoma-related research.
For research use only. We do not sell to patients.
- CAS No.: 956181-19-4
- Formula: C33H26N2O6
- Molecular Weight:546.57
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
ATOX1-IN-1 (Compound 8) (48 h) inhibits the viability of HepG2 and Huh7 hepatocellular carcinoma cells with IC50 values of 16.5 μM and 22.0 μM, respectively, and exhibits high selectivity for cancer cells over immortalized hepatocytes THLE-2[1].
ATOX1-IN-1 (10 μM) with 10 μM Cisplatin exerts more significant antiproliferative and proapoptotic effects on HepG2 and Huh7 hepatocellular carcinoma cells[1].
ATOX1-IN-1 (5-15 μM) inhibits the NOTCH1/HES1 signaling pathway in HepG2 and Huh7 hepatocellular carcinoma cells in a concentration-dependent manner in vitro, and reduces the mRNA and protein expression levels of NOTCH1 and HES1[1].
ATOX1-IN-1 (5-15 μM) increases intracellular copper levels in HepG2 and Huh7 hepatocellular carcinoma cells in a concentration-dependent manner[1].
ATOX1-IN-1 (5-15 μM) enhances DNA methylation of the NOTCH1 promoter in HepG2 and Huh7 hepatocellular carcinoma cells in a concentration-dependent manner in vitro[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (6-8 weeks old, 18-22 g, equal male/female ratio, subcutaneous HepG2 xenograft model)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; once daily for 10 days
-
Result:Reduced tumor volume and proliferation marker (Ki67, PCNA) expression compared to the control group.
Produced a significantly greater tumor inhibition effect when combined with cisplatin than either single agent, with the combination group showing the smallest tumor volume, lowest Ki67 and PCNA expression, and no obvious pathological changes in major organs (heart, liver, lung, kidney, gastrointestinal tract).
Chemical Information
-
CAS No. 956181-19-4
-
Molecular Weight 546.57
-
Formula C33H26N2O6
-
SMILES
O=C(N[C@@H](CC1=CNC2=C1C=CC=C2)C(OC3=CC=C(C(C=CC=C4)=C4C(O5)=O)C5=C3C)=O)OCC6=CC=CC=C6
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz